Pierre d'Epenoux

[NEWS] Biocytogen Announces ADC Innovator Tubulis GmbH Has Signed Global Exclusive License Agreement for Single Antibody Biocytogen, a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine. The antibody was generated using Biocytogen’s proprietary RenMice® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to address areas of high unmet clinical need in cancer treatment. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased that Tubulis has exercised its option, which reflects the international competitiveness and translational potential of our fully human antibody discovery platform. We look forward to seeing this antibody advance through Tubulis’ powerful ADC development engine and into clinical development to benefit patients around the world.” Jonas Helma-Smets, PhD, CSO and co-founder of Tubulis, stated: “Our goal is to drive innovation in ADC development and deliver uniquely positioned ADC therapeutics that can improve treatment outcomes to patients with solid tumors. The R&D collaboration with Biocytogen has yielded an antibody candidate that we believe fits well with our ADC technology platforms and that may support us in the development of a novel therapeutic candidate.” Under the terms of the agreement, Biocytogen will receive an upfront payment and is eligible for certain development, regulatory, and commercial milestone payments, and single-digit royalties on net sales. #Biocytogen #Tubulis #AntibodyDiscovery #RenMicePlatform #ADCTherapeutics #CancerTherapeutics #OncologyInnovation #DrugDevelopment #BiotechCollaboration #NovelTherapeutics #BiopharmaPartnerships

105

2 commentaires

As Jean-Luc Delay begins his role as the new Chair of the EFPIA Innovation Board Sponsored Committee (IBSC), he shares his vision to restore Europe’s competitiveness and accelerate patient access to medicines. “I’m honored to step into the role of Chair of EFPIA’s Innovation Board Sponsored Committee. Our collective goal is to ensure Europe remains a global leader in pharmaceutical innovation by championing legislation that accelerates clinical trials and the translation of science into impactful healthcare solutions. We’ll continue working with EU policymakers, fostering inclusive dialogue with innovators, and seizing opportunities like the EU Biotech Act to drive investment, access, and innovation for patients. I look forward to co-developing sustainable solutions that help build a healthier and more competitive Europe.” #WeWontRest

294

13 commentaires

Caroline Ven, CEO of pharma.be calls for a #European #investment commitment in #health, comparable to the one European leaders have agreed on regarding defense spending, in an exclusive interview with Le journal du Médecin & Artsenkrant https://lnkd.in/eTEjERnc #innovation #innovatie #geneesmiddelen #médicaments #vaccins #gezondheid #gezondheidszorg #santé #soinsdesanté #toekomst #future #België #Belgique #Europe #Europa EFPIA - European Federation of Pharmaceutical Industries and Associations

41

Our Chief Technology Officer, Sergei Yakneen will be heading to BioTechX EU Congress in Basel on Monday, 6 October. BiotechX is Europe’s largest biotechnology conference and Sergei will open the event at 9am CEST with his keynote “AI Models from Atoms to Humans: the Era of Rational In Silico Drug Design”. AI is already helping us to understand disease like never before, but where are we going next? Sergei will explore tackling program failures like efficacy and safety, selecting the right targets, and going beyond individual proteins to examine complexes and molecular machines. He’ll set out a future where applying frontier AI will help unlock deeper scientific insights and faster breakthroughs with an ambition to solve all disease. If you are planning to attend, don't miss it. Find out more about the event here: bit.ly/42EClLB

165

2 commentaires